Rational design of HIV-1 entry inhibitors

Methods in Molecular Biology

Volumn 993, Issue , 2013, Pages 185-204

  Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

CCR5; CD4; CXCR4; Entry inhibitor; Gp120; Gp41; HIV 1

Indexed keywords

A 12; ADS J 1; ADS J 2; ADS J1; ADS J2; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYANOVIRIN N; GLS 22; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; KRH 1636; LIGAND; MACROCYCLIC COMPOUND; NBD 09027; NBD 10007; PEPTIDOMIMETIC AGENT; PLERIXAFOR; RANTES; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANALYTIC METHOD; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMBINATORIAL LIBRARY; COMPUTER MODEL; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; BIOLOGY; CHEMISTRY; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW; VIRUS ENTRY;

ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HIV-1; HUMANS; VIRUS INTERNALIZATION;

EID: 84884235855     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-342-8_13     Document Type: Article

References (64)

1. Biscone MJ, Pierson TC, Doms RW (2002) Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol 2:529-533
2. Starr-Spires LD, Collman RG (2002) HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med 22:681-701
3. Hertje M, Zhou M, Dietrich U (2010) Inhibition of HIV-1 entry: multiple keys to close the door. ChemMedChem 5:1825-1835
4. Sodroski JG (1999) HIV-1 entry inhibitors in the side pocket. Cell 99:243-246
5. Caffrey M (2011) HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 19:191-197
6. Jiang S, Debnath AK (2000) Development of HIV entry inhibitors targeted to the coiled coil regions of gp41. Biochem Biophys Res Commun 269:641-646
7. Jiang S, Zhao Q, Debnath AK (2002) Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 8:563-580
8. Vita C, Drakopoulou E, Vizzavona J et al (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci USA 96:13091-13096
9. Wyatt R, Kwong PD, Desjardins E et al (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711
10. Martin L, Stricher F, Misse D et al (2003) Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21:71-76
11. Li H, Guan Y, Szczepanska A et al (2007) Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. Bioorg Med Chem 15:4220-4228
12. Zhao Q, Ma L, Jiang S et al (2005) Identi fication of N-phenyl-N ¢ -(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225
13. Madani N, Schon A, Princiotto AM et al (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16:1689-1701
14. Yoshimura K, Harada S, Shibata J et al (2010) Enhanced exposure of human immunode ficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84:7558-7568
15. Lalonde JM, Elban MA, Courter JR et al (2011) Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 19:91-101
16. Yamada Y, Ochiai C, Yoshimura K et al (2010) CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 20:354-358
17. Kwon YD, Finzi A, Wu X et al (2012) Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 109: 5663-5668
18. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43-53
19. Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623
20. Grant JA, Gallardo MA, Pickup BT (1996) A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J Comput Chem 17: 1653-1666
21. Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749
22. Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750-1759
23. Caporuscio F, Ta fiA, Gonzalez E et al (2009) A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Bioorg Med Chem Lett 19:6087-6091
24. Cornell WD, Cieplak P, Bayly CI et al (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179-5197
25. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857
26. Boyd MR, Gustafson KR, McMahon JB et al (1997) Discovery of cyanovirin-N, a novel human immunode ficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41:1521-1530
27. Dey B, Lerner DL, Lusso P et al (2000) Multiple antiviral activities of cyanovirin-N: blocking of human immunode ficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74:4562-4569
28. Esser MT, Mori T, Mondor I et al (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunode ficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73:4360-4371
29. Patsalo V, Raleigh DP, Green DF (2011) Rational and computational design of stabilized variants of cyanovirin-N that retain af finity and speci ficity for glycan ligands. Biochemistry 50:10698-10712
30. Neffe AT, Meyer B (2004) A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Angew Chem Int Ed Engl 43:2937-2940
31. Wulfken J (2000) Development of CD4 binding peptides as inhibitors of HIV infection. Ph.D. Thesis, University of Hamburg, Germany
32. Neffe AT, Bilang M, Gruneberg I, Meyer B (2007) Rational optimization of the binding af finity of CD4 targeting peptidomimetics with potential anti HIV activity. J Med Chem 50:3482-3488
33. Lee DY, Lin X, Paskaleva EE et al (2009) Palmitic acid is a novel CD4 fusion inhibitor that blocks HIV entry and infection. AIDS Res Hum Retroviruses 25:1231-1241
34. Lin X, Paskaleva EE, Chang W et al (2011) Inhibition of HIV-1 infection in ex vivo cervical tissue model of human vagina by palmitic acid: implications for a microbicide development. PLoS One 6:e24803
35. Morris GM, Goodsell DS, Halliday RS et al (1998) Automated docking using Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19: 1639-1662
36. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273
37. Weissenhorn W, Dessen A, Harrison SC et al (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430
38. Lu M, Blacklow SC, Kim PS (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2: 1075-1082
39. Debnath AK, Radigan L, Jiang S (1999) Structure-based identi fication of small molecule antiviral compounds targeted to the gp41 core structure of the human immunode ficiency virus type 1. J Med Chem 42:3203-3209
40. Good AC, Ewing TJ, Gschwend DA, Kuntz ID (1995) New molecular shape descriptors: application in database screening. J Comput Aided Mol Des 9:1-12
41. Shoichet BK, Bodian DL, Kuntz ID (1992) Molecular docking using shape descriptors. J Comput Chem 13:380-397
42. Jiang S, Lin K, Lu M (1998) A conformationspeci fic monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 72:10213-10217
43. Jiang S, Lu H, Liu S et al (2004) N-substituted pyrrole derivatives as novel human immunode ficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48:4349-4359
44. Liu B, Joseph RW, Dorsey BD et al (2009) Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation. Bioorg Med Chem Lett 19:5693-5697
45. Clark M, Meshkat S, Talbot GT et al (2009) Fragment-based computation of binding free energies by systematic sampling. J Chem Inf Model 49:1901-1913
46. Liu K, Lu H, Hou L et al (2008) Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51:7843-7854
47. Wang Y, Lu H, Zhu Q et al (2010) Structurebased design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg Med Chem Lett 20:189-192
48. Welch BD, VanDemark AP, Heroux A et al (2007) Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA 104: 16828-16833
49. Eckert DM, Malashkevich VN, Hong LH et al (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103-115
50. Tan JJ, Zhang B, Cong XJ et al (2011) Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41. Med Chem 7:309-316
51. Cong XJ, Tan JJ, Liu M et al (2010) Computational study of binding mode of N-substituted pyrrole derivatives to HIV-1 gp41. Prog Biochem Biophys 37:904-915
52. Wang CX, Cong XJ, Kong R et al (2010) Binding mode of HIV-1 gp41 with its inhibitor NB-2. J Beijing Univ Technol 36: 1118-1123
53. Kellenberger E, Springael JY, Parmentier M et al (2007) Identi fication of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem 50: 1294-1303
54. Jain AN (2003) Sur flex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499-511
55. Farzan M, Choe H, Vaca L et al (1998) A tyrosine-rich region in the N terminus of CCR5 is important for human immunode ficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol 72:1160-1164
56. Farzan M, Vasilieva N, Schnitzler CE et al (2000) A tyrosine-sulfated peptide based on the N-terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 275:33516-33521
57. Farzan M, Mirzabekov T, Kolchinsky P et al (1999) Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96: 667-676
58. Huang CC, Lam SN, Acharya P et al (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934
59. Acharya P, Dogo-Isonagie C, Lalonde JM et al (2011) Structure-based identi fication and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry. ACS Chem Biol 6:1069-1077
60. Nardese V, Longhi R, Polo S et al (2001) Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct Biol 8:611-615
61. Vangelista L, Longhi R, Sironi F et al (2006) Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochem Biophys Res Commun 351:664-668
62. Lusso P, Vangelista L, Cimbro R et al (2011) Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J 25:1230-1243
63. Perez-Nueno VI, Pettersson S, Ritchie DW et al (2009) Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J Chem Inf Model 49:810-823
64. McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51:578-596